# Amplatzer Septal Occluder

Product · id `cardio:amplatzer-septal-occluder` · Cardiovascular Atlas · release `f6f6f1b6f50379ed` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Amplatzer ASO; ASO

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A device from Abbott that closes a hole between the two upper heart chambers (an atrial septal defect) through a catheter. NHLBI lists catheter repair and surgery as ways to close such a hole. The US FDA approved it in 2001 for atrial septal defects of the secundum type with echocardiographic evidence of the defect and clinical evidence of extra work for the right lower chamber (a left-to-right shunt of 1.5 to 1 or an enlarged right ventricle), and for closing the opening left after a fenestrated Fontan procedure. The FDA approval does not state an age range.

## Technical summary

Amplatzer Septal Occluder (ASO) and Amplatzer Exchange System, FDA product code MLV, PMA P000039, approved 2001-12-05. The approval order lists secundum atrial septal defect closure for patients with echocardiographic evidence of an ostium secundum defect and clinical evidence of right ventricular volume overload, and closure of the fenestration in patients who had a fenestrated Fontan procedure. NHLBI lists catheter procedures among the ways to repair a simple defect of this kind when it does not heal by itself. No trial results are recorded here.

## Claims, with the population each applies to

## Context: United States PMA approval P000039: Amplatzer Septal Occluder for secundum atrial septal defect

Recipient: Recipient not specified; Population: Patients with echocardiographic evidence of an ostium secundum atrial septal defect and clinical evidence of right ventricular volume overload, and patients who have had a fenestrated Fontan procedure and now need the fenestration closed. The order gives no age range.; Care setting: Not stated in the FDA record; Geography: United States (decision by the US Food and Drug Administration); Life stage: Not stated in the FDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)

### The Amplatzer Septal Occluder is FDA-approved for closing atrial septal defects in the secundum position through a catheter, in patients with echocardiographic evidence of an ostium secundum defect and clinical evidence of right ventricular volume overload (a left-to-right shunt of 1.5 to 1 or right ventricular enlargement). The approval order also covers closing the fenestration after a fenestrated Fontan procedure. This states what the device is approved for. It is not a finding about how well the device works or how safe it is.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients with echocardiographic evidence of an ostium secundum atrial septal defect and clinical evidence of right ventricular volume overload, and patients who have had a fenestrated Fontan procedure and now need the fenestration closed. The order gives no age range.; Care setting: Not stated in the FDA record; Geography: United States (decision by the US Food and Drug Administration); Life stage: Not stated in the FDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Limitations: Describes the approval scope only. The order cited gives no age range, no trial results and no comparison with surgery; the summary of safety and effectiveness was not read. The link to adult congenital heart disease is the atlas's filing of the record: the approval does not say the patients are adults, and the NHLBI pages describe atrial septal defects as defects present at birth.
- Last checked: 2026-10-14
- Sources:
  1. Supports: FDA premarket approval record P000039: Amplatzer Septal Occluder and Exchange System (original PMA approval) (openFDA record) (Regulator, edition The openFDA PMA record returned on 2026-10-14 for P000039 (the earliest record by decision date, which is the original approval, with no supplement number), from a dataset last updated 2026-10-05. The FDA PMA database page was not fetched for this record.) <https://api.fda.gov/device/pma.json?search=pma_number:P000039&sort=decision_date:asc&limit=1>
     Locator: results\[0\].ao\_statement. Retrieved 2026-10-14T18:21:11Z. Source state: Current. Snapshot hash: ff5d636a50d50cfd28b1ca78fcca5a6658ca09be5ce1eb48e76f199b2ec8844f.
     How it applies: The approval order statement: the approved indications.
  2. Supports: FDA premarket approval record P000039: Amplatzer Septal Occluder and Exchange System (original PMA approval) (openFDA record) (Regulator, edition The openFDA PMA record returned on 2026-10-14 for P000039 (the earliest record by decision date, which is the original approval, with no supplement number), from a dataset last updated 2026-10-05. The FDA PMA database page was not fetched for this record.) <https://api.fda.gov/device/pma.json?search=pma_number:P000039&sort=decision_date:asc&limit=1>
     Locator: results\[0\].decision\_date. Retrieved 2026-10-14T18:21:11Z. Source state: Current. Snapshot hash: ff5d636a50d50cfd28b1ca78fcca5a6658ca09be5ce1eb48e76f199b2ec8844f.
     How it applies: Date of the approval.
  3. Background: Congenital Heart Defects: Types (NHLBI) (Webpage, edition Page fetched 2026-10-14. The page says it was last updated on March 24, 2022.) <https://www.nhlbi.nih.gov/health/congenital-heart-defects/types>
     Locator: Atrial septal defect section. Retrieved 2026-10-14T18:22:37Z. Source state: Current. Snapshot hash: 9d927334f1b5cfb2fa5e6b3c8eddb6bad4bf0d633b0b7ff03f4281ef357a6588.
     How it applies: NHLBI describes what an atrial septal defect is.
  4. Background: Congenital Heart Defects: Treatment (NHLBI) (Webpage, edition Page fetched 2026-10-14. The page says it was last updated on March 24, 2022.) <https://www.nhlbi.nih.gov/health/congenital-heart-defects/treatment>
     Locator: Procedures section. Retrieved 2026-10-14T18:22:38Z. Source state: Current. Snapshot hash: 2461de12d2112bac2ca9dc9b277263fbf6804c9ee8185d3d7d49a21deef6a8ca.
     How it applies: NHLBI names cardiac catheterization as a way to repair a simple defect such as an atrial septal defect.

### On 2001-12-05 the US Food and Drug Administration approved the Amplatzer Septal Occluder (ASO) and the Amplatzer Exchange System under PMA P000039, product code MLV, applicant ABBOTT MEDICAL. The approval order states the occluder is indicated for occlusion of atrial septal defects in the secundum position, and also for patients who have had a fenestrated Fontan procedure and now need the fenestration closed. Patients indicated for atrial septal defect closure have echocardiographic evidence of an ostium secundum defect and clinical evidence of right ventricular volume overload (a left-to-right shunt of 1.5:1 or right ventricular enlargement). The Exchange System is for removing an Amplatzer delivery sheath and exchanging it for one of equal or larger diameter.

- Category: Regulatory
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients with echocardiographic evidence of an ostium secundum atrial septal defect and clinical evidence of right ventricular volume overload, and patients who have had a fenestrated Fontan procedure and now need the fenestration closed. The order gives no age range.; Care setting: Not stated in the FDA record; Geography: United States (decision by the US Food and Drug Administration); Life stage: Not stated in the FDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Limitations: openFDA copies the approval order statement and may lose characters; where a symbol is missing it is not restored here. The FDA PMA database page, the approval order and the summary of safety and effectiveness were not read, so conditions of approval and trial results are not recorded. An approval is a regulatory decision and not a finding about how well the device works for any person. openFDA's own disclaimer says not to rely on it to make decisions regarding medical care. The order gives no age range. Closing the opening in a heart is also done by surgery; this record does not compare the two.
- Last checked: 2026-10-14
- Sources:
  1. Supports: FDA premarket approval record P000039: Amplatzer Septal Occluder and Exchange System (original PMA approval) (openFDA record) (Regulator, edition The openFDA PMA record returned on 2026-10-14 for P000039 (the earliest record by decision date, which is the original approval, with no supplement number), from a dataset last updated 2026-10-05. The FDA PMA database page was not fetched for this record.) <https://api.fda.gov/device/pma.json?search=pma_number:P000039&sort=decision_date:asc&limit=1>
     Locator: results\[0\].pma\_number. Retrieved 2026-10-14T18:21:11Z. Source state: Current. Snapshot hash: ff5d636a50d50cfd28b1ca78fcca5a6658ca09be5ce1eb48e76f199b2ec8844f.
     How it applies: The PMA number of this record.
  2. Supports: FDA premarket approval record P000039: Amplatzer Septal Occluder and Exchange System (original PMA approval) (openFDA record) (Regulator, edition The openFDA PMA record returned on 2026-10-14 for P000039 (the earliest record by decision date, which is the original approval, with no supplement number), from a dataset last updated 2026-10-05. The FDA PMA database page was not fetched for this record.) <https://api.fda.gov/device/pma.json?search=pma_number:P000039&sort=decision_date:asc&limit=1>
     Locator: results\[0\].applicant. Retrieved 2026-10-14T18:21:11Z. Source state: Current. Snapshot hash: ff5d636a50d50cfd28b1ca78fcca5a6658ca09be5ce1eb48e76f199b2ec8844f.
     How it applies: The applicant, as FDA writes the name.
  3. Supports: FDA premarket approval record P000039: Amplatzer Septal Occluder and Exchange System (original PMA approval) (openFDA record) (Regulator, edition The openFDA PMA record returned on 2026-10-14 for P000039 (the earliest record by decision date, which is the original approval, with no supplement number), from a dataset last updated 2026-10-05. The FDA PMA database page was not fetched for this record.) <https://api.fda.gov/device/pma.json?search=pma_number:P000039&sort=decision_date:asc&limit=1>
     Locator: results\[0\].trade\_name. Retrieved 2026-10-14T18:21:11Z. Source state: Current. Snapshot hash: ff5d636a50d50cfd28b1ca78fcca5a6658ca09be5ce1eb48e76f199b2ec8844f.
     How it applies: The trade name FDA gives this record.
  4. Supports: FDA premarket approval record P000039: Amplatzer Septal Occluder and Exchange System (original PMA approval) (openFDA record) (Regulator, edition The openFDA PMA record returned on 2026-10-14 for P000039 (the earliest record by decision date, which is the original approval, with no supplement number), from a dataset last updated 2026-10-05. The FDA PMA database page was not fetched for this record.) <https://api.fda.gov/device/pma.json?search=pma_number:P000039&sort=decision_date:asc&limit=1>
     Locator: results\[0\].decision\_date. Retrieved 2026-10-14T18:21:11Z. Source state: Current. Snapshot hash: ff5d636a50d50cfd28b1ca78fcca5a6658ca09be5ce1eb48e76f199b2ec8844f.
     How it applies: ISO date of the decision.
  5. Supports: FDA premarket approval record P000039: Amplatzer Septal Occluder and Exchange System (original PMA approval) (openFDA record) (Regulator, edition The openFDA PMA record returned on 2026-10-14 for P000039 (the earliest record by decision date, which is the original approval, with no supplement number), from a dataset last updated 2026-10-05. The FDA PMA database page was not fetched for this record.) <https://api.fda.gov/device/pma.json?search=pma_number:P000039&sort=decision_date:asc&limit=1>
     Locator: results\[0\].decision\_code. Retrieved 2026-10-14T18:21:11Z. Source state: Current. Snapshot hash: ff5d636a50d50cfd28b1ca78fcca5a6658ca09be5ce1eb48e76f199b2ec8844f.
     How it applies: FDA decision code: APPR is an approval.
  6. Supports: FDA premarket approval record P000039: Amplatzer Septal Occluder and Exchange System (original PMA approval) (openFDA record) (Regulator, edition The openFDA PMA record returned on 2026-10-14 for P000039 (the earliest record by decision date, which is the original approval, with no supplement number), from a dataset last updated 2026-10-05. The FDA PMA database page was not fetched for this record.) <https://api.fda.gov/device/pma.json?search=pma_number:P000039&sort=decision_date:asc&limit=1>
     Locator: results\[0\].product\_code. Retrieved 2026-10-14T18:21:11Z. Source state: Current. Snapshot hash: ff5d636a50d50cfd28b1ca78fcca5a6658ca09be5ce1eb48e76f199b2ec8844f.
     How it applies: FDA product code of this record.
  7. Supports: FDA premarket approval record P000039: Amplatzer Septal Occluder and Exchange System (original PMA approval) (openFDA record) (Regulator, edition The openFDA PMA record returned on 2026-10-14 for P000039 (the earliest record by decision date, which is the original approval, with no supplement number), from a dataset last updated 2026-10-05. The FDA PMA database page was not fetched for this record.) <https://api.fda.gov/device/pma.json?search=pma_number:P000039&sort=decision_date:asc&limit=1>
     Locator: results\[0\].ao\_statement. Retrieved 2026-10-14T18:21:11Z. Source state: Current. Snapshot hash: ff5d636a50d50cfd28b1ca78fcca5a6658ca09be5ce1eb48e76f199b2ec8844f.
     How it applies: FDA approval order statement: the approved indication, quoted in fragments.
  8. Background: FDA premarket approval record P000039: Amplatzer Septal Occluder and Exchange System (original PMA approval) (openFDA record) (Regulator, edition The openFDA PMA record returned on 2026-10-14 for P000039 (the earliest record by decision date, which is the original approval, with no supplement number), from a dataset last updated 2026-10-05. The FDA PMA database page was not fetched for this record.) <https://api.fda.gov/device/pma.json?search=pma_number:P000039&sort=decision_date:asc&limit=1>
     Locator: meta.disclaimer. Retrieved 2026-10-14T18:21:11Z. Source state: Current. Snapshot hash: ff5d636a50d50cfd28b1ca78fcca5a6658ca09be5ce1eb48e76f199b2ec8844f.
     How it applies: openFDA's own disclaimer about relying on its data.

## Guidance, authorization and access

### Regulatory decision `cardio:regdec-fda-p000039`

- Product: Amplatzer Septal Occluder (`cardio:amplatzer-septal-occluder`)
- Authority: U.S. Food and Drug Administration (`core:fda`)
- Decision: Approval, 2001-12-05
- Product version: Amplatzer Septal Occluder (ASO) and Amplatzer Exchange System (original approval)
- Pathway: PMA
- Submission: P000039
- Product code: MLV
- Device class: III
- Indication: Occlusion of atrial septal defects in the secundum position (with echocardiographic evidence of an ostium secundum defect and clinical evidence of right ventricular volume overload), and closure of the fenestration in patients who have had a fenestrated Fontan procedure. The Exchange System is for exchanging an Amplatzer delivery sheath.
- Jurisdictions: United States; note: United States
- Applies to: Recipient: Recipient not specified; Population: Patients with echocardiographic evidence of an ostium secundum atrial septal defect and clinical evidence of right ventricular volume overload, and patients who have had a fenestrated Fontan procedure and now need the fenestration closed. The order gives no age range.; Care setting: Not stated in the FDA record; Geography: United States (decision by the US Food and Drug Administration); Life stage: Not stated in the FDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Basis: claim `cardio:claim-fda-p000039-approval`

## Connected pages

- Applicant on P000039 is ABBOTT MEDICAL; the sources read do not say who makes the device: Abbott (`cardio:abbott`)
- FDA approval scope only: closing secundum atrial septal defects through a catheter, in patients with echocardiographic evidence of the defect and right ventricular volume overload (a shunt of 1.5 to 1 or an enlarged right ventricle); the approval states no age range and reports no trial results: Adult congenital heart disease (`cardio:adult-congenital-heart-disease`) [a claim, not a settled fact; see claim `cardio:claim-amplatzer-approved-scope` and its context]
- Filed under this front: Procedures and surgery (`cardio:front-procedures-and-surgery`)

## Provenance

Content hash: ffa15e5551a7adcbad746bfb55ba67ddb37c9e2753bbd7bd6f95f32e3ca9806e
Last substantive edit: 2026-10-14
Evidence last checked: 2026-10-14